Caris Life Sciences, Inc.
Business
Caris Life Sciences is a precision medicine company that develops and commercializes comprehensive molecular profiling solutions for oncology using whole exome sequencing, whole transcriptome sequencing, and whole genome sequencing combined with artificial intelligence and machine learning. The company offers tissue-based profiling (MI Profile), blood-based profiling (Caris Assure), and early-detection solutions (Caris Detect) to physicians, academic institutions, and biopharma partners. Caris operates two clinical laboratories and an R&D facility in Arizona, serving over 6,000 ordering physicians across the United States and international markets through distributors and direct contracts.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total revenue | 812 | 412 | 306 | |
| Selling and marketing expense | 168 | 153 | 143 | |
| General and administrative expense (see note 11) | 225 | 169 | 149 | |
| Research and development expense | 102 | 114 | 117 | |
| Total costs and operating expenses | 767 | 669 | 626 | |
| Income (Loss) from operations | 45 | −257 | −320 | |
| Interest income | 16 | 7 | 11 | |
| Interest expense | −57 | −50 | −32 | |
| Changes in fair value of financial instruments | −52 | 18 | 11 | |
| Other expense, net | −21 | −349,000 | −13 | |
| Total other expense, net | −113 | −25 | −22 | |
| Loss before income taxes and provision for income taxes | −68 | −282 | −341 | |
| Provision for income taxes | 0 | 0 | 0 | |
| Net loss | −68 | −282 | −341 | |
| Unrealized gain on available-for-sale securities | 0 | 7,000 | −2 | |
| Foreign currency translation adjustments | 726,000 | −15,000 | 180,000 | |
| Comprehensive loss | −67 | −282 | −343 | |
| Deemed dividend from Series D redeemable convertible preferred stock (see note 6) | −384 | 0 | 0 | |
| Adjustments of redeemable convertible preferred stock to redemption value | −85 | −96 | −121 | |
| Net loss attributable to common shareholders basic | −538 | −378 | −463 | |
| Net loss attributable to common shareholders diluted | −538 | −378 | −463 | |
| Net loss per share attributable to common shareholders, basic (in dollars per share) | −3.22 | −10.66 | −13.24 | |
| Net loss per share attributable to common shareholders, diluted (in dollars per share) | −3.22 | −10.66 | −13.24 | |
| Weighted-average shares used in computing net loss per share attributable to common shareholders, basic (in shares) | 167 | 35 | 35 | |
| Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted (in shares) | 167 | 35 | 35 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-06-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | 798 | — | 65 | — | — | |
| Short-term marketable securities | 2 | — | 2 | — | — | |
| Accounts receivable | 112 | — | 88 | — | — | |
| Supplies | 64 | — | 40 | — | — | |
| Prepaid expenses and other current assets | 22 | — | 20 | — | — | |
| Total current assets | 998 | — | 216 | — | — | |
| Property and equipment, net | 63 | — | 68 | — | — | |
| Goodwill | 19 | — | 19 | — | — | |
| Other assets | 45 | — | 41 | — | — | |
| Total assets | 1,126 | — | 344 | — | — | |
| Accounts payable | 39 | — | 28 | — | — | |
| Accrued expenses and other current liabilities | 88 | — | 78 | — | — | |
| Current portion of indebtedness | 169,000 | — | 60 | — | — | |
| Total current liabilities | 127 | — | 165 | — | — | |
| Long-term indebtedness, net of debt discounts | 379 | — | 319 | — | — | |
| Warrant liabilities | 0 | — | 92 | — | — | |
| Other long-term liabilities | 42 | — | 44 | — | — | |
| Total liabilities | 548 | — | 621 | — | — | |
| Commitments and contingencies (see note 10) | — | — | — | — | — | |
| Redeemable convertible preferred stock | 0 | 2,446 | 2,222 | 2,125 | 1,954 | |
| Preferred stock | 0 | — | 0 | — | — | |
| Common stock | 283,000 | — | 38,000 | — | — | |
| Treasury stock | −17 | — | −330,000 | — | — | |
| Additional paid-in capital | 3,142 | — | 0 | — | — | |
| Related party promissory note receivable (see note 7) | 0 | — | −27 | — | — | |
| Accumulated deficit | −2,549 | — | −2,472 | — | — | |
| Accumulated other comprehensive income | 936,000 | — | 210,000 | — | — | |
| Total shareholders' equity (deficit) | 577 | — | −2,499 | −2,145 | −1,702 | |
| Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit) | 1,126 | — | 344 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 23 | 49 | 49 | |
| Stock-based compensation expense | 70 | 19 | 15 | |
| Non-cash operating lease expense | 6 | 6 | 4 | |
| Amortization of debt discounts | 13 | 7 | 5 | |
| Changes in fair value of financial instruments | 52 | −18 | −11 | |
| Loss on debt extinguishment | 20 | 0 | 11 | |
| Other | 1 | 4 | −1 | |
| Accounts receivable | −30 | −34 | −15 | |
| Supplies | −21 | 5 | −4 | |
| Prepaid expenses and other current assets | −5 | −1 | 5 | |
| Other assets | 48,000 | 121,000 | −588,000 | |
| Accounts payable | 11 | −226,000 | 7 | |
| Accrued expenses and other liabilities | 11 | 803,000 | 1 | |
| Net cash provided by (used in) operating activities | 83 | −245 | −276 | |
| Maturities of marketable securities | 0 | 61 | 300 | |
| Purchases of marketable securities | 0 | 0 | −63 | |
| Purchases of property and equipment | −16 | −8 | −22 | |
| Net cash provided by (used in) investing activities | −16 | 53 | 215 | |
| Payments made on finance lease obligations | −106,000 | −157,000 | −743,000 | |
| Proceeds from exercise of stock options | 8 | 2 | 2 | |
| Payment of taxes withheld from net settlement of exercised options and vested RSUs | −19 | 0 | 0 | |
| Payment of deferred offering costs | −8 | −1 | 0 | |
| Payment of third-party debt issuance costs | 0 | 0 | −2 | |
| Proceeds from the 2023 term loan, net of issuance costs | 0 | 200 | 191 | |
| Repurchase of common stock | −113,000 | 0 | 0 | |
| Repayment of the Original Term Loans | 0 | 0 | −180 | |
| Issuance of the 2025 Convertible Notes, net of issuance costs | 28 | 0 | 0 | |
| Issuance of the 2025 Warrants | 10 | 0 | 0 | |
| Payments of 2023 term loan amendment fee | −4 | 0 | 0 | |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 528 | 0 | 0 | |
| Net cash provided by financing activities | 665 | 200 | 10 | |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 130,000 | −4,000 | 62,000 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 732 | 8 | −51 | |
| Interest paid | 44 | 49 | 16 | |
| Operating cash flow used for operating leases | 12 | 11 | 12 | |
| Operating cash flow used for finance leases | 35,000 | 36,000 | 78,000 | |
| Operating leases | 4 | 725,000 | 5 | |
| Finance leases | 312,000 | 42,000 | 0 | |
| Property and equipment included in accounts payable and accrued liabilities | 2 | 2 | 894,000 | |
| Non-cash considerations | 6 | 0 | 0 | |
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | 2,386 | 0 | 0 | |
| Exercise of warrants upon initial public offering | 148 | 0 | 0 | |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | 9 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Caris Life Sciences, Inc.'s CIK number?
Caris Life Sciences, Inc.'s SEC CIK number is 0002019410 (2019410). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Caris Life Sciences, Inc.'s SEC filings?
All of Caris Life Sciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Caris Life Sciences, Inc. last report earnings?
Caris Life Sciences, Inc. (CAI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0002019410-26-000040). This is Caris Life Sciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Caris Life Sciences, Inc.'s most recent earnings 8-K?
Caris Life Sciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0002019410-26-000040. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Caris Life Sciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →